Investors Increasingly Favoring Generative AI Healthcare Startups

Startup funding in healthcare may be scarce these days, but the situation is not entirely hopeless.

Generative AI is attracting some sizable financing, thanks to its potential to revolutionize healthcare via advancements in efficiency, precision, and patient outcomes. As overall healthcare startup funding dropped by 65% from January 2022 to June 2024, investments in generative AI healthcare startups have increased more than five-fold during that same period, surging from $81 million to $439 million, according to GlobalData.

“In 2024, there is a significant increase in venture capital (VC) investments and strategic partnerships focused on generative AI,” GlobalData Practice Head for Disruptive Tech Manish Dixit said. “This surge is driven by the technology’s potential to revolutionize healthcare operations, enhance precision in diagnostics, and improve patient outcomes. AI-assisted decision-making is becoming a cornerstone for healthcare companies aiming to reduce operational costs and optimize their services.”

GlobalData’s Deals Database estimates generative AI VC deals in the first half of this year to be valued at $444.7 million. Some of the notable funding deals during those six months included a $150 million fund raised by Kore.ai to continue advancing its AI platform; $70 million raised by Ambience Healthcare to grow both its operations and business clientele; and $60 million capital secured by Omniscient Neurotechnology (o8t) to increase its U.S market share and advance product development efforts.
 
Non-VC deals during the review period included a $1.7 billion partnership agreement between Isomorphic Labs and Eli Lilly to advance drug design approaches. Another notable partnership—valued at $674 million—occurred between VantAI and Bristol Myers Squibb to expand therapeutic programs. In addition, Stemline Therapeutics and Insilico Medicine entered a $512 million licensing agreement to develop AI-powered treatments for hormone-sensitive cancers and other oncology indications.
 
“Startups are leveraging generative AI to interpret vast amounts of medical data, reduce paperwork, and optimize AI-driven workflows to further advance in their fields,” GlobalData Senior Disruptive Tech Analyst Prathyusha Paruchuri noted. “Companies like DeepCure, Automera, BeeKeeperAI, Alaffia Health, and InpharmD are addressing diverse healthcare challenges, with funding ranging from $6.05 million to $24.6 million in 2024, underscoring their innovative solutions and market potential. Even though healthcare companies are facing funding squeeze, investments in generative AI are an exception. The technology has a transformative impact on diagnostics, patient engagement, and remote care. However, concerns about its ability to handle emergencies and its finite knowledge base highlight the need for cautious and regulated adoption.”